Boston Scientific Corp. (BSX): Price and Financial Metrics

Boston Scientific Corp. (BSX): $38.01

0.74 (+1.99%)

POWR Rating

Component Grades














  • BSX scores best on the Sentiment dimension, with a Sentiment rank ahead of 93.02% of US stocks.
  • BSX's strongest trending metric is Growth; it's been moving down over the last 179 days.
  • BSX's current lowest rank is in the Momentum metric (where it is better than 19.56% of US stocks).

BSX Stock Summary

  • BSX has a higher market value than 95.77% of US stocks; more precisely, its current market capitalization is $63,988,603,333.
  • In terms of twelve month growth in earnings before interest and taxes, Boston Scientific Corp is reporting a growth rate of 404.27%; that's higher than 94.68% of US stocks.
  • In terms of volatility of its share price, BSX is more volatile than only 3.05% of stocks we're observing.
  • If you're looking for stocks that are quantitatively similar to Boston Scientific Corp, a group of peers worth examining would be IDXX, ALC, ZTS, ABB, and MMM.
  • Visit BSX's SEC page to see the company's official filings. To visit the company's web site, go to

BSX Valuation Summary

  • BSX's price/sales ratio is 5.7; this is 50% higher than that of the median Healthcare stock.
  • BSX's price/sales ratio has moved up 2.7 over the prior 243 months.
  • Over the past 243 months, BSX's price/sales ratio has gone up 2.7.

Below are key valuation metrics over time for BSX.

Stock Date P/S P/B P/E EV/EBIT
BSX 2021-08-31 5.7 4 122.2 78.3
BSX 2021-08-30 5.7 4 121.4 77.8
BSX 2021-08-27 5.7 4 121.3 77.8
BSX 2021-08-26 5.7 4 120.9 77.5
BSX 2021-08-25 5.7 4 121.3 77.8
BSX 2021-08-24 5.7 4 121.4 77.8

BSX Growth Metrics

    Its 2 year price growth rate is now at 21.74%.
  • The year over year revenue growth rate now stands at -6.14%.
  • The 5 year revenue growth rate now stands at 40.56%.
BSX's revenue has moved up $3,058,000,000 over the prior 52 months.

The table below shows BSX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 11,888 1,870 985
2021-09-30 11,470 2,065 1,100
2021-06-30 11,197 2,243 526
2021-03-31 10,123 1,869 201
2020-12-31 9,913 1,508 -115
2020-09-30 10,109 1,527 3,685

BSX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • BSX has a Quality Grade of C, ranking ahead of 73.14% of graded US stocks.
  • BSX's asset turnover comes in at 0.362 -- ranking 120th of 186 Medical Equipment stocks.
  • INGN, ECIA, and ATRC are the stocks whose asset turnover ratios are most correlated with BSX.

The table below shows BSX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.362 0.669 0.051
2021-03-31 0.328 0.649 0.032
2020-12-31 0.324 0.650 0.015
2020-09-30 0.331 0.672 0.003
2020-06-30 0.344 0.682 0.022
2020-03-31 0.386 0.704 0.043

BSX Price Target

For more insight on analysts targets of BSX, see our BSX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $51.08 Average Broker Recommendation 1.4 (Moderate Buy)

BSX Stock Price Chart Interactive Chart >

Price chart for BSX

BSX Price/Volume Stats

Current price $38.01 52-week high $47.49
Prev. close $37.27 52-week low $34.98
Day low $37.09 Volume 5,870,000
Day high $38.12 Avg. volume 9,008,839
50-day MA $39.61 Dividend yield N/A
200-day MA $42.12 Market Cap 54.34B

Boston Scientific Corp. (BSX) Company Bio

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiologyinterventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiologycardiac surgeryvascular surgeryendoscopyoncologyurology and gynecology. (Source:Wikipedia)

BSX Latest News Stream

Event/Time News Detail
Loading, please wait...

BSX Latest Social Stream

Loading social stream, please wait...

View Full BSX Social Stream

Latest BSX News From Around the Web

Below are the latest news stories about Boston Scientific Corp that investors may wish to consider to help them evaluate BSX as an investment opportunity.

Boston Scientific Stock Earns Relative Strength Rating Upgrade; Hits Key Threshold

A Relative Strength Rating upgrade for Boston Scientific shows improving technical performance.

Investor''s Business Daily | February 23, 2022

Boston Scientific Corporation -- Moody's upgrades Boston Scientific to Baa1, outlook stable

Rating Action: Moody's upgrades Boston Scientific to Baa1, outlook stableGlobal Credit Research - 23 Feb 2022New York, February 23, 2022 -- Moody's Investors Service ("Moody's") upgraded Boston Scientific Corporation's ("Boston Scientific") senior unsecured rating to Baa1 from Baa2. Moody's also affirmed the company's Prime-2 commercial paper rating.

Yahoo | February 23, 2022

Peripheral Vascular Devices Market is Estimated to Surpass USD 13 Billion by 2026

New York, USA, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Peripheral Vascular Devices Market is Estimated to Surpass USD 13 Billion by 2026 As per DelveInsight analysis, the demand for Peripheral Vascular Devices is increasing due to the rapid rise in cardiovascular and peripheral vascular diseases prevalence, as well as the approval of new and improved products by market players along with the rising frequency of lifestyle disorders such as diabetes and hypertension. DelveInsight''s Peripheral Vascular Devices Market Insights report provides the current and forecast Peripheral Vascular Devices market, upcoming device innovation, individual market shares, challenges, drivers, barriers, and market trends and key Peripheral Vascular Device companies in the market. Key Takeaways from the Peripheral...

Benzinga | February 22, 2022

FTC approves modifications to Boston Scientific divestiture agreement

The U.S. Federal Trade Commission said it has approved certain modifications to medical device company Boston Scientific Corp’s divestiture agreements.

Reuters | February 18, 2022

FTC approves modifications to Boston Scientific divestiture agreement By Reuters

FTC approves modifications to Boston Scientific divestiture agreement | February 18, 2022

Read More 'BSX' Stories Here

BSX Price Returns

1-mo -6.54%
3-mo -15.51%
6-mo -11.85%
1-year -13.46%
3-year -10.84%
5-year 37.57%
YTD -10.52%
2021 18.16%
2020 -20.50%
2019 27.96%
2018 42.56%
2017 14.61%

Continue Researching BSX

Want to see what other sources are saying about Boston Scientific Corp's financials and stock price? Try the links below:

Boston Scientific Corp (BSX) Stock Price | Nasdaq
Boston Scientific Corp (BSX) Stock Quote, History and News - Yahoo Finance
Boston Scientific Corp (BSX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.5649 seconds.